279 related articles for article (PubMed ID: 15802532)
1. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
2. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
3. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
5. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
7. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
Spanswick VJ; Craddock C; Sekhar M; Mahendra P; Shankaranarayana P; Hughes RG; Hochhauser D; Hartley JA
Blood; 2002 Jul; 100(1):224-9. PubMed ID: 12070031
[TBL] [Abstract][Full Text] [Related]
8. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
9. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
10. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
[TBL] [Abstract][Full Text] [Related]
11. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma.
Xie J; Zhang L; Li M; Du J; Zhou L; Yang S; Zeng L; Li Z; Wang G; Wang D
BMC Cancer; 2014 Jan; 14():11. PubMed ID: 24400589
[TBL] [Abstract][Full Text] [Related]
13. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
14. [Reversal of multidrug resistance of the drug resistant human multiple myeloma cell line MOLP-2/R by curcumin and its relation with FA/BRCA pathway].
Xiao H; Zhang KJ; Zuo XL
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):33-7. PubMed ID: 19563033
[TBL] [Abstract][Full Text] [Related]
15. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.
Gkotzamanidou M; Terpos E; Bamia C; Munshi NC; Dimopoulos MA; Souliotis VL
Blood; 2016 Sep; 128(9):1214-25. PubMed ID: 27443291
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R.
Xiao H; Xiao Q; Zhang K; Zuo X; Shrestha UK
Ann Hematol; 2010 Apr; 89(4):399-404. PubMed ID: 19756599
[TBL] [Abstract][Full Text] [Related]
17. DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein.
Pichierri P; Averbeck D; Rosselli F
Hum Mol Genet; 2002 Oct; 11(21):2531-46. PubMed ID: 12354779
[TBL] [Abstract][Full Text] [Related]
18. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
19. In vitro evidence for homologous recombinational repair in resistance to melphalan.
Wang ZM; Chen ZP; Xu ZY; Christodoulopoulos G; Bello V; Mohr G; Aloyz R; Panasci LC
J Natl Cancer Inst; 2001 Oct; 93(19):1473-8. PubMed ID: 11584063
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
Efferth T; Fabry U; Osieka R
Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]